Poxel Announces Positive Results From the First Stage of the Ongoing PXL770 Phase 1 Trial Jun 20, 2016
Poxel Presents New Data on Imeglimin’s Dual Mechanism of Action at the American Diabetes Association’s 76th Scientific Sessions Jun 13, 2016
Poxel to Present Imeglimin Data at the American Diabetes Association’s 76th Scientific Sessions May 17, 2016
Poxel has been Granted U.S. Composition of Matter Patent for Direct AMPK Activator PXL770 for the Potential Treatment of Type 2 Diabetes and Related Disorders Mar 29, 2016
Poxel Appoints Jonae R. Barnes as Senior Vice President Investor Relations and Public Relations, Based in Boston Mar 14, 2016